Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    HealthTech BioActives, leading globally in Flavonoids and Vitamin B12 Derivatives.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Menu

    Mebufotenin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atai, Beckley Psytech Show Positive Phase 2a Results For Bpl-003
    Atai, Beckley Psytech Show Positive Phase 2a Results For Bpl-003

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3154533/0/en/atai-Life-Sciences-and-Beckley-Psytech-Report-Positive-Phase-2a-Data-Demonstrating-Improved-Outcomes-with-a-Two-Dose-Induction-Regimen-of-BPL-003-in-Patients-with-Treatment-Resista.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019385/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    Beckley Psytech begins Phase IIa treatment resistant depression trial
    Beckley Psytech begins Phase IIa treatment resistant depression trial

    22 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/beckley-psytech-depression-trial/

    CLINICALTRIALSARENA
    22 Dec 2022
    Share Share
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003

    21 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221221005221/en

    BUSINESSWIRE
    21 Dec 2022
    Share Share